Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 12:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 4,778 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Cancers Clear all

Conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma
Interventions: Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Denver, Colorado • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Advanced Cancers
Interventions: Co-ArgI-PEG; Drug
Lead sponsor: Immedica Pharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 7 more

Conditions: Non-Small Cell Lung Cancer
Interventions: PR104, docetaxel, Granulocyte colony-stimulating factor; Drug
Lead sponsor: Proacta, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 25
States / cities: San Diego, California • Miami, Florida • Chicago, Illinois + 22 more

Conditions: Head and Neck Cancer
Interventions: Pralatrexate With Vitamin B12 and Folic Acid; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
Interventions: psychosocial assessment and care, Quality of Life Assessments; Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: KRdD followed by auto-HCT, KRdD only; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Birmingham, Alabama • Portland, Oregon • Nashville, Tennessee + 1 more

Conditions: Lyphoma, B-Cell, Leukemia, B-cell, Multiple Myeloma, Hematologic Malignancies
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2050
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hodgkin Disease
Interventions: Nivolumab, Doxorubicin, Vinblastine, Dacarbazine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 14
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 8 more

Conditions: Relapsed/Refractory Multiple Myeloma
Interventions: Ipilimumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 73 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, amifostine trihydrate, cyclophosphamide, melphalan, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of Kentucky; Other
Eligibility: 14 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 4
States / cities: Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more

Conditions: Neoplasms
Interventions: RG4733; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 7
States / cities: Aurora, Colorado • Boston, Massachusetts • New Brunswick, New Jersey + 2 more

Conditions: Hepatitis C Virus
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 815,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: rhPSMA-7.3 (18F) Injection, Positron emission tomography scan; Drug · Diagnostic Test
Lead sponsor: Blue Earth Diagnostics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more

Conditions: Breast Cancer, Neutropenia
Interventions: F-627, Neulasta® (pegfilgrastim); Drug
Lead sponsor: EVIVE Biotechnology; Industry
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Anderson, Indiana

Conditions: Multiple Myeloma, End Stage Renal Disease
Interventions: Cyclophosphamide, anti-thymocyte globulin, Kidney transplant, Thymic irradiation, Bone marrow transplant from a related donor; Drug · Procedure · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
Interventions: CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]; Drug
Lead sponsor: Cytovation AS; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more

Conditions: Multiple Myeloma (MM)
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: New Orleans, Louisiana • Dallas, Texas

Conditions: Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition
Interventions: defined green tea catechin extract, gene expression analysis, protein analysis, laboratory biomarker analysis; Dietary Supplement · Genetic · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: CMV pp65 peptide, hTERT I540/R572Y/D988Y multipeptide vaccine, pneumococcal polyvalent vaccine, survivin Sur1M2 peptide vaccine; Biological
Lead sponsor: University of Maryland Greenebaum Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Advanced Metastatic Castration Resistant Prostate Cancer
Interventions: INV-9956; Drug
Lead sponsor: Shenzhen Ionova Life Sciences Co., Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Scottsdale, Arizona • Newport Beach, California • Orange, California + 4 more

Conditions: Malignant Glioma
Interventions: Dendritic vaccine pulsed with multiple peptides, The first booster vaccine phase:, The second booster vaccine phase:; Biological
Lead sponsor: Frank Lieberman; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Entre Culturas: Navigating Culture, Identity, and HIV Risk; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lirilumab, Urelumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Little Rock, Arkansas • Baltimore, Maryland • New York, New York + 3 more

Conditions: Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS
Interventions: BYL719, MEK162; Drug
Lead sponsor: Array BioPharma; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 8
States / cities: La Jolla, California • Tampa, Florida • Chicago, Illinois + 5 more

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation

Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)

Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect

A Multiple Ascending Dose Study of R4733 in Patients With Advanced Solid Tumors.

Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Study to Evaluate t(11;14) Status and BCL2 Expression in Adult Participants With Multiple Myeloma (MM)

Green Tea Extract in Treating Patients With Monoclonal Gammopathy of Undetermined Significance and/or Smoldering Multiple Myeloma

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

Motiv82Change: an HIV Prevention Study for Young Latino Men

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors